Q1 Earnings Estimate for MariMed Issued By Noble Financial

MariMed Inc. (OTCMKTS:MRMD) – Analysts at Noble Financial issued their Q1 2026 earnings per share estimates for MariMed in a research report issued on Monday, March 16th. Noble Financial analyst J. Gomes expects that the company will earn ($0.01) per share for the quarter. Noble Financial also issued estimates for MariMed’s Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.02) EPS and FY2027 earnings at ($0.02) EPS.

Separately, Zacks Research upgraded MariMed from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. One analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

MariMed Stock Down 1.3%

Shares of OTCMKTS:MRMD opened at $0.08 on Tuesday. MariMed has a 1-year low of $0.07 and a 1-year high of $0.23. The company has a debt-to-equity ratio of 1.44, a current ratio of 1.00 and a quick ratio of 0.38. The stock has a market cap of $30.66 million, a P/E ratio of -2.58 and a beta of 1.11. The firm has a fifty day moving average price of $0.09 and a 200 day moving average price of $0.11.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.